Study | No. of thalassemia patients | Method of strain acquisition | T2* | GLS | GCS | GRS | T2* correlation with GLS | T2* correlation with GCS | T2* correlation with GRS | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
r | P-value | r | P-value | r | P-value | |||||||
Garceau et al. [35] (2011) | 45 | 2D-STE: LV GLS (A4C, A3C, A2C), LV GCS (PSAX) | 23 ± 13 | –18.0 ± 3.0 | –22.0 ± 5.0 | - | –0.65 | < 0.05* | –0.39 | < 0.05* | - | - |
Cusmà Piccione et al. [38] (2013) | 32 | 2D-STE: LV GLS (A4C, A2C), LV GRS, LV GCS (PSAX) | 37.7 ± 5.5 | –17.9 ± 3.5* | –20.5 ± 5.1 | 36.7 ± 8.2 | –0.53 | 0.001* | - | - | - | - |
Li et al. [39] (2016) | 24 | 3D-STE: LV GLS | 32.7 ± 16.7 | 28.0 ± 7.4* | - | - | 0.74 | < 0.001* | - | - | - | - |
Pizzino et al. [8] (2018) | 28 | 2D-STE: LV GLS (A4C, A3C, A2C), LV GCS (PSAX) | 40.5 (32 to 44) | –20.6 ± 2.8 | –19.5 ± 2.6 | –18.3 ± 2.0* | –0.41 | 0.031* | - | - | - | - |
Poorzand et al. [42] (2017) | 44 | 2D-STE: LV GLS (A4C, A3C, A2C), LASr, RASr (A4C) | 19.8 ± 10.3 | –19.4 ± 3.2 | - | –17.6 ± 2.6* | –0.42 | 0.001* | - | - | - | - |
Abtahi et al. [40] (2019) | 52 | 2D-STE: LV GLS (A4C, A3C, A2C) | 19.8 ± 10.3 | –19.4 ± 3.2 | –17.6 ± 2.6* | –21.6 ± 2.7 | –0.6 | 0.001* | - | - | - | - |
Fattahi et al. [20] (2021) | 48 | 2D-STE: LV GLS (A4C, A3C, A2C) 3D-STE: LV GLS, LVGCS | 24.2 (3 to 43) | –22.0 ± 4.6 | –30.1 ± 6.5 | –21.6 | –0.5a | < 0.05* | –0.49b | < 0.05* | - | - |
Alis et al. [13] (2022) | 42 | CMR-FT | 30.97 ± 10.84 | 16.85 ± 1.73 | 16.86 ± 1.96 | 28.25 ± 4.79 | - | - | 0.6 | < 0.0001* | - | |
Asadian et al. [37] (2021) | 154 | CMR-FT | 24.77 ± 11.18 | 18.07 ± 1.35 | 17.68 ± 1.78 | 39.82 ± 7.77 | 0.309 | < 0.001* | - | - | 0.368 | < 0.001* |
Ojha et al. [1] (2021) | 104 | CMR-FT | 31.37 (24.37 to 39.08) | − 14.53 ± 2.86 | –19.75 (–22.02 to –18.06) | 33.41 (27.58 to 41.09) | –0.17 | 0.10 | –0.16 | 0.12 | 0.24 | 0.02* |
Das et al. [3] (2022) | 89 | CMR-FT | - | –16.8 ± 3.80 | –18.2 ± 3.44 | 46.76 ± 9.74 | –0.194 | 0.085 | –0.217 | 0.053 | 0.232 | 0.038 |